Breast Cancer Screening Market, Global Forecast by Screening Test, Population, Countries, Company Analysis

Breast Cancer Screening Market, Global Forecast by Screening Test, Population, Countries, Company Analysis

  • May 2020 •
  • 380 pages •
  • Report ID: 5891712 •
  • Format: PDF
Breast Cancer Screening Market, Global Forecast by Screening Test, Population, Countries, Company Analysis

Globally, breast cancer is considered one of the most common cancers in women around the world.
Breast cancer is also a leading cause of death from cancer in the world’s least developed nations. Every year 1.7 Million new cases are diagnosed with breast cancer, and approximately 60% of deaths due to breast cancer occur around the world. Breast cancer is a form of cancer that occurs in the tissue of the breast. Formations of a lump in a breast and red patches on the skin are some of the typical breast cancer signs. Obesity, lack of physical activity, overexposure to radiation, and consuming alcohol are among the risk factors for breast cancer growth. According to the research report, the Global Breast Cancer Screening Market is anticipated to reach US$ 51.8 Billion by the end of the year 2026, with double-digit CAGR during the forecast period.

COVID – 19 impact on Breast Cancer Screening Market Worldwide
The COVID-19 outbreak could have an impact on all drug companies manufacturing, supply chain, and clinical trial operations. In the year 2020, the global breast cancer screening population, as well as the market, will decline. The primary reason for this decline is a coronavirus. For a complete analysis, read our report as to how COVID – 19 is affecting every quarter of the year 2020 and when the market will revive? Other challenges of breast cancer screening are high medication costs, therapy-related adverse effects, and lengthy product approval times are responsible for curbing market growth.

Growth Factors for Global Breast Cancer Screening Market
The key growth factors of the breast cancer market are the increasing number of females suffering from breast cancer, growing older women population is the primary factor for the growth of the market. In addition to this adoption of an unhealthy lifestyle, the rise of the female geriatric population, exposure to harmful radiation, and increased policy measures have contributed to market growth.

Also, the incidence of breast cancer is rising in the lower-income countries due to an increase in life expectancy, adaption to increasing urbanization and western lifestyles. World over, more than half of the breast cancer cases now have been reported from low and middle-income countries (LMICs) as these countries do not have proper breast screening programs; hence, the majority of cases are diagnosed in late stages. Growing breast cancer incidences & mortality in the low and middle-income countries, these countries need to develop an effective breast cancer screening program strategy that will address the earlier deduction of incidence of breast cancer for women.

Some of the major breast cancer screening technologies which help to find breast cancer after diagnosis are as follows. Breast cancer screening technologies are MRI, Ultrasound, and mammography screening. Mammography screening aims at minimizing the death rate from breast cancer by identifying unsuspected breast cancers early. The breast cancer mammography screening market is flourishing, driven by advances in technologies and delivery models, product innovations, increasing use of digital mammography equipment, and growing public awareness. Globally, awareness about breast cancer is increasing, with more women coming forward for their yearly mammograms after the age of 40 years.

Besides, around the world, governments have introduced screening programs for early detection that entails a routine check-up. Several countries are already offering breast cancer screening programs for women, and the number is establishing these programs are steadily increasing. In Germany, for example, the “Mammo Screening” program exists since 2002. In the United States, most states are introducing laws requiring health insurance companies to reimburse all or part of the cost of screening mammograms. Furthermore, the NHS Breast Screening Program in the United Kingdom provides free breast screening every three years for all women aged. Also, continuous efforts are taken by various government agencies and NGOs, the worldwide market for breast cancer screening.

This latest study report “Breast Cancer Screening Market, Population, By Screening Tests [Mammography, Magnetic Resonance Imaging (MRI) & Ultrasound] Countries (United States, Canada, France, United Kingdom, Germany, Italy, Spain, Netherlands, Norway, Switzerland, China, India, Korea, Japan, Singapore, Thailand, Malaysia, Brazil, Australia, New Zealand, South Africa, United Arab Emirates, Saudi Arabia), Company Analysis (AstraZeneca, Novartis, Sanofi, Pfizer, Bayer AG)” provides a detailed and comprehensive insight of the Breast Cancer Screening Market.

Screening Tests - Mammography is the Most Common Test for Breast Cancer Screening
Mammography is sophisticated medical imaging that uses a low-dose x-ray device to view human breasts indoors. Mammography plays a vital role in the early detection and treatment of women with breast diseases. Breast Magnetic Resonance Imaging (MRI) or breast ultrasound, in addition to mammography, also helps detect breast cancer in women.

Countries – Total 23 Countries Market & Population for Breast Cancer Screening, Mammography Screening, MRI Screening & Ultrasound Screening has been studied in the report

The study includes a comprehensive Breast cancer overview of Canada, France, Italy, Spain, Switzerland, Netherlands, Norway, India, Australia, Japan, Korea, Singapore, Thailand, Malaysia, Brazil, New Zealand, South Africa, United Arab Emirates and Saudi Arabia Breast Cancer, Mammography, Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population and Market.

The report provides a complete analysis of the key Growth Drivers, Challenges, Market, Screened Population, and their projections for the upcoming years till 2026.

All the companies have been studied from two points
• Recent Developments
• Sales Analysis

Company Analysis
• AstraZeneca
• Novartis
• Sanofi
• Pfizer
• Bayer AG

Breast Cancer Screening Market & Population - By Screening Tests Covered in the Report
• Mammography
• Magnetic Resonance Imaging (MRI)
• Ultrasound

23 Regions Covered in the Report:

1. United States
2. Canada
3. United Kingdom
4. France
5. Germany
6. Italy
7. Spain
8. Netherlands
9. Norway
10. Switzerland
11. India
12. China
13. Japan
14. Korea
15. Singapore
16. Thailand
17. Malaysia
18. Brazil
19. Australia
20. New Zealand
21. South Africa
22. United Arab Emirates
23. Saudi Arabia

Globally, breast cancer is considered one of the most common cancers in women around the world. Breast cancer is also a leading cause of death from cancer in the world’s least developed nations. Every year 1.7 Million new cases are diagnosed with breast cancer, and approximately 60% of deaths due to breast cancer occur around the world. Breast cancer is a form of cancer that occurs in the tissue of the breast. Formations of a lump in a breast and red patches on the skin are some of the typical breast cancer signs. Obesity, lack of physical activity, overexposure to radiation, and consuming alcohol are among the risk factors for breast cancer growth. According to the research report, the Global Breast Cancer Screening Market is anticipated to reach US$ 51.8 Billion by the end of the year 2026, with double-digit CAGR during the forecast period.

COVID – 19 impact on Breast Cancer Screening Market Worldwide
The COVID-19 outbreak could have an impact on all drug companies manufacturing, supply chain, and clinical trial operations. In the year 2020, the global breast cancer screening population, as well as the market, will decline. The primary reason for this decline is a coronavirus. For a complete analysis, read our report as to how COVID – 19 is affecting every quarter of the year 2020 and when the market will revive? Other challenges of breast cancer screening are high medication costs, therapy-related adverse effects, and lengthy product approval times are responsible for curbing market growth.

Growth Factors for Global Breast Cancer Screening Market
The key growth factors of the breast cancer market are the increasing number of females suffering from breast cancer, growing older women population is the primary factor for the growth of the market. In addition to this adoption of an unhealthy lifestyle, the rise of the female geriatric population, exposure to harmful radiation, and increased policy measures have contributed to market growth.

Also, the incidence of breast cancer is rising in the lower-income countries due to an increase in life expectancy, adaption to increasing urbanization and western lifestyles. World over, more than half of the breast cancer cases now have been reported from low and middle-income countries (LMICs) as these countries do not have proper breast screening programs; hence, the majority of cases are diagnosed in late stages. Growing breast cancer incidences & mortality in the low and middle-income countries, these countries need to develop an effective breast cancer screening program strategy that will address the earlier deduction of incidence of breast cancer for women.

Some of the major breast cancer screening technologies which help to find breast cancer after diagnosis are as follows. Breast cancer screening technologies are MRI, Ultrasound, and mammography screening. Mammography screening aims at minimizing the death rate from breast cancer by identifying unsuspected breast cancers early. The breast cancer mammography screening market is flourishing, driven by advances in technologies and delivery models, product innovations, increasing use of digital mammography equipment, and growing public awareness. Globally, awareness about breast cancer is increasing, with more women coming forward for their yearly mammograms after the age of 40 years.

Besides, around the world, governments have introduced screening programs for early detection that entails a routine check-up. Several countries are already offering breast cancer screening programs for women, and the number is establishing these programs are steadily increasing. In Germany, for example, the “Mammo Screening” program exists since 2002. In the United States, most states are introducing laws requiring health insurance companies to reimburse all or part of the cost of screening mammograms. Furthermore, the NHS Breast Screening Program in the United Kingdom provides free breast screening every three years for all women aged. Also, continuous efforts are taken by various government agencies and NGOs, the worldwide market for breast cancer screening.

This latest study report “Breast Cancer Screening Market, Population, By Screening Tests [Mammography, Magnetic Resonance Imaging (MRI) & Ultrasound] Countries (United States, Canada, France, United Kingdom, Germany, Italy, Spain, Netherlands, Norway, Switzerland, China, India, Korea, Japan, Singapore, Thailand, Malaysia, Brazil, Australia, New Zealand, South Africa, United Arab Emirates, Saudi Arabia), Company Analysis (AstraZeneca, Novartis, Sanofi, Pfizer, Bayer AG)” provides a detailed and comprehensive insight of the Breast Cancer Screening Market.

Screening Tests - Mammography is the Most Common Test for Breast Cancer Screening
Mammography is sophisticated medical imaging that uses a low-dose x-ray device to view human breasts indoors. Mammography plays a vital role in the early detection and treatment of women with breast diseases. Breast Magnetic Resonance Imaging (MRI) or breast ultrasound, in addition to mammography, also helps detect breast cancer in women.

Countries – Total 23 Countries Market & Population for Breast Cancer Screening, Mammography Screening, MRI Screening & Ultrasound Screening has been studied in the report

The study includes a comprehensive Breast cancer overview of Canada, France, Italy, Spain, Switzerland, Netherlands, Norway, India, Australia, Japan, Korea, Singapore, Thailand, Malaysia, Brazil, New Zealand, South Africa, United Arab Emirates and Saudi Arabia Breast Cancer, Mammography, Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population and Market.

The report provides a complete analysis of the key Growth Drivers, Challenges, Market, Screened Population, and their projections for the upcoming years till 2026.

All the companies have been studied from two points
• Recent Developments
• Sales Analysis

Company Analysis
• AstraZeneca
• Novartis
• Sanofi
• Pfizer
• Bayer AG

Breast Cancer Screening Market & Population - By Screening Tests Covered in the Report
• Mammography
• Magnetic Resonance Imaging (MRI)
• Ultrasound

23 Regions Covered in the Report:

1. United States
2. Canada
3. United Kingdom
4. France
5. Germany
6. Italy
7. Spain
8. Netherlands
9. Norway
10. Switzerland
11. India
12. China
13. Japan
14. Korea
15. Singapore
16. Thailand
17. Malaysia
18. Brazil
19. Australia
20. New Zealand
21. South Africa
22. United Arab Emirates
23. Saudi Arabia